Compare Lowe`s Companies Inc (LOW) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Medpace Holdings Inc — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Lowe`s Companies Inc is far larger — about 6.3× Medpace Holdings Inc's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Medpace Holdings Inc for 14 Days on average.
| LOW | MEDP | |
|---|---|---|
Market Cap | $105.96B | $16.82B |
Volume | 4,039,547 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $630.19 |
52-Week Low | $179.50 | $393.42 |
Typical Hold Time | 98 Days | 14 Days |
Enterprise Value | $144.81B | $16.44B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.85, up 4.03% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with 7.35% net margins and reasonable valuation at 15.96 P/E. Recent drone delivery innovation with DoorDash and Alphabet demonstrates operational adaptation amid challenging home improvement market conditions.
Outlook remains cautious with housing market headwinds, though analyst consensus targets $244.09 (29% upside). Key risks include interest rate sensitivity and competitive pressure from Home Depot. The company's Dividend King status and consistent cash flow generation provide stability for long-term investors.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
